These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Re-evaluating the New Committee on Infectious Diseases Recommendations for Palivizumab Use in Premature Infants. Yogev R; Krilov LR; Fergie JE; Weiner LB Pediatr Infect Dis J; 2015 Sep; 34(9):958-60. PubMed ID: 26107347 [No Abstract] [Full Text] [Related]
3. Antimicrobial Stewardship Programs (ASP): Perspective on Problems and Potential. Cunha CB R I Med J (2013); 2018 Jun; 101(5):18-21. PubMed ID: 29857599 [No Abstract] [Full Text] [Related]
4. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis. Kua KP; Lee SWH Pharmacotherapy; 2017 Jun; 37(6):755-769. PubMed ID: 28423192 [TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era. Resch B; Egger B; Kurath-Koller S; Urlesberger B Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland. Groves HE; Jenkins L; Macfarlane M; Reid A; Lynn F; Shields MD Pediatr Pulmonol; 2016 Apr; 51(4):379-85. PubMed ID: 26808981 [TBL] [Abstract][Full Text] [Related]
7. Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands. Kool-Houweling LM; Penning-van Beest FJ; Bezemer ID; van Lingen RA; Herings RM Acta Paediatr; 2015 Sep; 104(9):927-32. PubMed ID: 26073782 [TBL] [Abstract][Full Text] [Related]
8. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab. Chan P; Li A; Paes B; Abraha H; Mitchell I; Lanctôt KL; Pediatr Infect Dis J; 2015 Dec; 34(12):e290-7. PubMed ID: 26780032 [TBL] [Abstract][Full Text] [Related]
9. Computer-Assisted Antimicrobial Recommendations for Optimal Therapy: Analysis of Prescribing Errors in an Antimicrobial Stewardship Trial. Schwartz DN; McConeghy KW; Lyles RD; Wu U; Glowacki RC; Itokazu GS; Kieszkowski P; Xiang Y; Hota B; Weinstein RA Infect Control Hosp Epidemiol; 2017 Jul; 38(7):857-859. PubMed ID: 28571589 [TBL] [Abstract][Full Text] [Related]
11. The Working Group for Revision of "Guidelines for the Use of Palivizumab in Japan": A Committee Report. Okada K; Mizuno M; Moriuchi H; Kusuda S; Morioka I; Mori M; Okamoto K; Okada K; Yoshihara S; Yamagishi H; Yokoyama U; Kubota T; Kudo K; Takagi M; Ito S; Kanamori Y; Sasahara Y Pediatr Int; 2020 Nov; 62(11):1223-1229. PubMed ID: 33078556 [No Abstract] [Full Text] [Related]
12. Association Between Updated Guideline-Based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections. Grindeland CJ; Mauriello CT; Leedahl DD; Richter LM; Meyer AC Pediatr Infect Dis J; 2016 Jul; 35(7):728-32. PubMed ID: 27078122 [TBL] [Abstract][Full Text] [Related]
13. Restrictive Palivizumab Use Does Not Lead to Increased Morbidity and Mortality in Pediatric Hematopoietic Stem Cell Transplantation Patients. Teusink-Cross A; Davies SM; Danziger-Isakov L; El-Bietar J; Grimley MS Biol Blood Marrow Transplant; 2016 Oct; 22(10):1904-1906. PubMed ID: 27422147 [TBL] [Abstract][Full Text] [Related]
15. Receipt of palivizumab before birth hospitalization discharge among preterm infants in the United States. La Gamma EF; Kumar VR; Wadhawan R; Ye S; Sifakis F; Ycas J; Ambrose CS Am J Perinatol; 2015 Sep; 32(11):1017-23. PubMed ID: 25877742 [TBL] [Abstract][Full Text] [Related]
16. Antibiotic use in the emergency department: Is there room for improvement? Ortega Romero M Emergencias; 2018 Oct; 30(5):292-294. PubMed ID: 30260111 [No Abstract] [Full Text] [Related]
18. Infection Control and Antimicrobial Stewardship. Lonks JR R I Med J (2013); 2018 Jun; 101(5):35-37. PubMed ID: 29857604 [TBL] [Abstract][Full Text] [Related]
19. Observed Effectiveness of Palivizumab for 29-36-Week Gestation Infants. Farber HJ; Buckwold FJ; Lachman B; Simpson JS; Buck E; Arun M; Valadez AM; Ruiz T; Alonzo J; Henry A; Cos-Okpalla N; Nguyen K; Brendel W; Small J; Glomb WB Pediatrics; 2016 Aug; 138(2):. PubMed ID: 27432850 [TBL] [Abstract][Full Text] [Related]
20. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Romero JR Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]